Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant
Nous verifions auprès de chaque centre si des nouvelles informations sont disponibles

2021-00135

Swiss cardiac amyloidosis registry (swiss-care)
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT04776824
Cardiac Amyloidosis
Tafamidis
CMR feature tracking
Strain
T1 and T2 Mapping
Outcomes
Source : Importé depuis le centre
Recrutement partiellement ouvert
Dernière modification : 2025/05/05
Type de recherche

Observationnel


Population cible

Condition médicale (spécialité visée)

Donnée non disponible

Profil des participants

Sexe(s) des participants

ALL

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

* Confirmed diagnosis of amyloidosis w/wo cardiac involvement
* General Consent

Exclusion Criteria:

* Inability to give consent or existence of a written or documented oral refusal of the data subject.\<18 years of age

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
Patients with confirmed amyloidosis Confirmed diagnosis of amyloidosis w/wo cardiac involvement Donnée non disponible
  • Inconnu
  • Patients with confirmed amyloidosis
    État du recrutement
    unknown
    Données à jour depuis : 5 mai 2025

    Description de l'étude

    Résumé de l'étude

    Cardiac transthyretin amyloidosis (ATTR), caused by ventricular depositions of misfolded transthyretin, results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickening, diastolic and systolic dysfunction to the development of terminal heart failure. Recently, treatment options for TTR amyloidosis have become available. However costs for therapy are enormous and previous trials were not able to differentiate between patients that might benefit from treatment and those without a need for treatment.

    the investigators study aims to determine markers, as assessed by cardiac magnet resonance imaging (CMR) feature tracking (FT) and T1- and T2- mapping, that might reliably indicate disease severity and could help to identify patients that might benefit from (ongoing) TTR stabilization treatment.

    Source : Importé depuis le centre

    Cardiac transthyretin amyloidosis (ATTR), the most common amyloidosis form with cardiac involvement, is caused by tissue deposition of misfolded TTR, a transport Protein for thyroxine and retinol. Ventricular depositions of amyloid fibrils results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickening, to diastolic and systolic dysfunction and finally chronic heart failure.

    While treatment options are now available, it remains unclear how to monitor therapy response and disease progression. No makers have been identified that predict outcome prior to initiation of therapy, thus patient selection for therapy remains challenging.

    The investigators study will address these issues and will provide systematically assessed CMR data before and over the course of 18 months after therapy initiation. Clinical and laboratory follow-up will be performed every 3-6 months. The investigators study is based on an open, uncontrolled, structured collection of retrospective and prospective data from all patients diagnosed with amyloidosis at the Inselspital Bern with the aim to follow patients undergoing therapy.

    The investigators hypothesize that CMR feature tracking (FT) and measures of T1- and T2- mapping, such as extracellular volume (ECV) may better correlate with disease severity and help to identify patients likely to benefit from (ongoing) TTR stabilizing therapy. Beside standard CMR assessments, the investigators will use CMR feature tracking to quantify global and regional myocardial function. FT has proven to be an excellent predictor in various cardiomyopathies.

    The proposed study will evaluate the potential of CMR to identify patients likely to benefit from therapy, monitor treatment response and balance individual patient benefit and health care cost.

    Source : Importé depuis le centre

    Sites

    Centres participants


    Dernière modification : 5 mai 2025
    Données à jour depuis : 7 mai
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT04776824